EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 3.0

Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study

Lei Sheng, Xuening Li iD, Jia Yu, Xiaodong Yang, Hui Li, Hongrong Xu

Drug Design, Development and Therapy · 2026-05 · Volume 20 · 1-13

DOI: 10.2147/dddt.s588573 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2026-05. Verfasst von Lei Sheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Atorvastatin, Valsartan, Benzhydryl Compounds, Glucosides. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinValsartanBenzhydryl CompoundsGlucosidesHumansDrug InteractionsMaleAdultYoung AdultAdministration, OralFemale

Stichwörter der Autor:innen

OATPchiglitazardrug-drug interactionpharmacokineticssafety

Substanzen

AtorvastatinValsartanBenzhydryl CompoundsGlucosidesempagliflozin

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Department of Clinical Pharmacology, Shenzhen Chipscreen Biosciences Co., Ltd, Shenzhen, Guangdong, People's Republic of China.

ORCID-Profile: Xuening Li

Zitieren

APA

Sheng, L., Li, X., Yu, J., Yang, X., Li, H., & Xu, H. (2026). Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study. Drug Design, Development and Therapy, Volume 20, 1-13. https://doi.org/10.2147/dddt.s588573

Vancouver

Sheng L, Li X, Yu J, Yang X, Li H, Xu H. Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study. Drug Design, Development and Therapy. 2026;Volume 20:1-13. doi:10.2147/dddt.s588573

BibTeX
@article{Sheng2026,
  author = {Sheng, Lei and Li, Xuening and Yu, Jia and Yang, Xiaodong and Li, Hui and Xu, Hongrong},
  title = {Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--13},
  doi = {10.2147/dddt.s588573}
}
Kostenlos starten →